Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
One of the prominent trends in the EMEA Cell Counting Market is the continuous evolution of automated cell counting technologies. These advancements contribute to enhanced accuracy, efficiency, and speed in cell counting processes. Automated systems are becoming increasingly popular in research and clinical settings, addressing the growing demand for reliable and quick cell analysis.
The EMEA region is experiencing a growing focus on cancer research, leading to an increased demand for precise cell counting solutions. Cell counting plays a crucial role in cancer studies, including drug development and personalized medicine. As a result, there is a notable surge in the adoption of specialized cell counting technologies tailored for cancer research applications.
Stem cell research has been steadily gaining traction in Europe, the Middle East and Africa. The flexibility of stem cells in regenerative medicine and therapeutic strategies is promoting the requirement for precise cell counting methods. The adoption of stem cell analysis-related specialized cell counting solutions is on the rise and this trend has gained prominence in EMEA Cell Counting Market.
In the EMEA region, biopharmaceutical sector has recorded significant development with many new biologicals coming into market. Biopharmaceuticals, including monoclonal antibodies and recombinant proteins are becoming more prevalent as a result of production. This growth greatly increases the requirement of cell-counting technologies that are used in bioprocessing and quality control.
Artificial intelligence (AI) is being adopted in the cell counting process. Cell counting systems powered by artificial intelligence eliminate manual image analysis and interpretation, thus reducing the time taken to process data as well as enhancing accuracy. This trend is significantly contributing to the development of cell counting technologies in terms of capabilities, especially across EMEA.
In clinical settings, there is an obvious focus on point-of-care cell counting solutions. Cell counting devices that are light, easy to use and offer fast cell analysis at the point of need continue gaining popularity. This trend is fueled by the fact that there are numerous applications in clinical diagnostics and patient management where real-time cell counting results which this technique provides, are very much necessary.
Key players in the EMEA Cell Counting Market are actively engaging in collaborations and partnerships to broaden their product portfolios and geographical reach. Collaborative efforts between technology providers and research institutions or pharmaceutical companies are fostering the development of innovative cell counting solutions and contributing to market growth.
The ongoing COVID-19 pandemic has underscored the importance of cell counting in various aspects, including vaccine development and virus research. The urgent need for accurate cell counting in these critical areas has led to an increased demand for cell counting technologies in the EMEA region. This impact is likely to have lasting effects on the market, emphasizing the role of cell counting in public health emergencies.
Europe Cell Counting Market Highlights:
Europe, the Middle East and Africa Cell Counting Market Overview
Europe, the Middle East and Africa Cell Counting Market Size was valued at USD 3.83 Billion in 2023. The Europe, the Middle East and Africa Cell Counting industry is projected to grow from USD 4.03 Billion in 2024 to USD 6.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.24% during the forecast period (2024 - 2032). Cell counting is used for the quantification of cells in life sciences. Cell counting is important for research and serves as one of the major steps in a majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. For instance, increase in the number of white blood cells (WBC) may indicate the possibility of cancerous growth in the body. Thus, cell counting is important for microbiology, hematologic and other medical specialties.
Rising prevalence of chronic diseases like cancer, TB (tuberculosis), AIDS along with increasing healthcare sector is driving the growth of this market. According to the World Health Organization, cancer was the second leading cause of death across the globe in 2015 and caused around 8.8 million deaths globally.
Moreover, it was estimated that more than 70% of the deaths due to cancer was caused in the middle and low-income countries. Moreover, increasing biotechnology industries and growing pharmaceutical sector is fuelling the market growth during the forecast period.
In 2017, according to the Biotechnology and Biological Sciences Research Council (BBSRC), the European industrial biotechnology industry is expected to reach approximately USD 53.2 billion by 2030 from 28 billion in 2013. However, lack of skilled professionals and the high cost of the cell counting equipment may restrain the market growth during the forecast period. The EMEA cell counting market is expected to grow at an approximate CAGR of 8.6% during the forecast period.
Europe, the Middle East and Africa Cell Counting Market Intended Audience
- Pharmaceutical companies
- Biotechnological institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Europe, the Middle East and Africa Cell Counting Market Segment Insights
Europe, the Middle East and Africa Cell Counting Product Insights
The market is segmented into instruments, consumables & accessories, and others. The instrument segment is sub-segmented into spectrophotometers, flow cytometers, hematology analyzers, cell counters, and others. The consumables & accessories segment is sub-segmented into reagents, microplates, and others.
Europe, the Middle East and Africa Cell Counting Application Insights
The market is segmented into hematology, microbiology, and others.
Europe, the Middle East and Africa Cell Counting End User Insights
The market is segmented into hospitals & clinics, research organizations, academic institutes, and others.
Europe, the Middle East and Africa Cell Counting Regional Insights
Europe is the largest EMEA cell counting market. Rising government support for research and a well-developed healthcare infrastructure within the region is driving the market growth within the region. This along with a huge patient population and growing healthcare expenditure is fuelling the market growth. According to the Cancer Research UK in 2014, about 356,860 new cases of cancer were reported within the region. Moreover, the total estimated deaths due to the same in 2014 were about 163,444.
Asia Pacific is the fastest growing region in the EMEA cell counting market. Presence of a huge patient population and continuously developing economies like India and China within the region drive the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020. Moreover, according to the National Institute of Cancer Prevention and Research in 2017, about 2.5 million people are living with cancer. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax boost the market growth. Additionally, increasing healthcare expenditures fuels the market within the region.
On the other hand, the Middle East & Africa holds the least share in the EMEA cell counting market due to the presence of poor economy, especially within the African region. Moreover, the absence of developed healthcare sector and stringent government policies are expected to restrain the market growth within the region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
Key players for EMEA cell counting market
- Bio-Rad Laboratories Inc. (U.S.)
- General Electric Company (U.S.)
- Agilent Technologies (U.S.)
- PerkinElmer Inc. (U.S.)
- Tecan Trading AG (Switzerland)
- BioTek Instruments, Inc. (U.S.)
- Danaher (U.S.)
- and Merck KGaA (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
